1. NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients. (February 2019) Authors: Bellocchi, M.C.; Carioti, L.; Aragri, M.; Fabeni, L.; Pipitone, R.; Brancaccio, G.; Sorbo, M.C.; di Maio, V.C.; Bronte, F.; Grimaudo, S.; Rizzo, V.; Frigeri, F.; Cantone, M.; Genderini, F.; Pinto, A.; Perno, C.F.; Craxì, A.; Gaeta, G.B.; Di Marco, V.; Ceccherini-Silberstein, F. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS. (23rd June 2022) Authors: Bruzzese, A.; Derudas, D.; Galli, M.; Martino, E. A.; Rocco, S.; Conticello, C.; Califano, C.; Giuliani, N.; Mangicavalli, S.; Farina, G.; Lombardo, A.; Brunori, M.; Rossi, E.; Antonioli, E.; Ria, R.; Zambello, R.; Di Renzo, N.; Mele, G.; Marcacci, G.; Pietrantuono, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THE ADDITION AT DAY 9 OF HD‐MTX TO THE (DA)‐EPOCH SCHEME WITH OR WITHOUT RITUXIMAB IS AN EFFECTIVE REGIMEN IN UNTREATED ADVANCED STAGE HIGH RISK LYMPHOMA: A FEASIBILITY STUDY. (12th June 2019) Authors: Farina, G.; Iaccarino, S.; Troiano, M.; Iovine, M.; Vigliotti, M.; Attingenti, E.; Camera, A.; Frigeri, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗